UNSPSC 51332001: Iloperidone

This classification denotes an antipsychotic agent with the molecular formula C24H27FN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VPO7KJ050N, chemically known as 4-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3-methoxyacetophenone but generally known as iloperidone, which bears US NIH Compound Identifier 71360. European Medicines Agency schedules Iloperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08135MIG.

UNSPSC 51332001 Iloperidone, a Commodity code, nominally identifies a single antipsychotic pharmaceutical product; however, recent state and local solicitations tagged under this code show little activity directly matching iloperidone procurement. The three posted opportunities instead address broader pharmaceutical supply categories — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local buyers using this code appear to include county health agencies (Seminole County, Florida), state health departments (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple jurisdictions including Oregon). The scope of work spans emergency response pharmaceuticals, pharmacy benefit program management, and bulk generic pharmaceutical distribution through wholesaler networks.

Activity concentrates in Florida, Texas, and Minnesota, with the Minnesota cooperative purchasing vehicle serving a multi-state footprint. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a two-year term with optional one-year renewal; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels; and Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with contract effectiveness July 1, 2026. The mismatch between the iloperidone code name and the actual pharmaceutical procurement activity in these opportunities suggests either miscoding or that this code functions as a general pharmaceutical catch-all in some jurisdictions' taxonomies.